Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Cash (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Change in Cash data on record, last reported at $392.3 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 1217.06% year-over-year to $392.3 million; the TTM value through Dec 2025 reached $345.0 million, up 75.87%, while the annual FY2025 figure was $345.0 million, 75.87% up from the prior year.
  • Change in Cash reached $392.3 million in Q4 2025 per OCUL's latest filing, up from -$46.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $392.3 million in Q4 2025 and bottomed at -$46.4 million in Q3 2025.
  • Average Change in Cash over 5 years is $25.4 million, with a median of -$16.3 million recorded in 2021.
  • Peak YoY movement for Change in Cash: plummeted 197.2% in 2021, then skyrocketed 1333.48% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$15.1 million in 2021, then dropped by 23.37% to -$18.6 million in 2022, then soared by 557.14% to $85.3 million in 2023, then plummeted by 141.19% to -$35.1 million in 2024, then surged by 1217.06% to $392.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $392.3 million in Q4 2025, -$46.4 million in Q3 2025, and $41.5 million in Q2 2025.